A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

NCT04262804 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Metastatic

Interventions

DRUG: Margetuximab
DRUG: Trastuzumab
DRUG: Chosen Chemotherapy (Capecitabine)
DRUG: Chosen Chemotherapy (Vinorelbine )
DRUG: Chosen Chemotherapy (Gemcitabine )

Sponsor

Zai Lab (Shanghai) Co., Ltd.